. 2008 Oct;193(4):279–288. doi: 10.1192/bjp.bp.108.050088

Table 3.

Analysis of probability of having a tardive dyskinesia event within 1 year for people with no tardive dyskinesia at baseline with adjustment for baseline covariates^a^,^b

	Olanzapine		Perphenazine		Quetiapine		Risperidone		Ziprasidone
Data-set	n	Estimated probablity (95% CI)	n	Estimated probablity (95% CI)	n	Estimated probablity (95% CI)	n	Estimated probablity (95% CI)	n	Estimated probablity (95% CI)	Overall P	Paired comparison
I: P v. O v. Q v. R^c
Schooler–Kane	182	0.01 (0.002–0.03)	183	0.03 (0.01–0.07)	179	0.02 (0.001–0.06)	179	0.01 (0.004–0.04)	–	–	0.25	NS
Modified
Schooler–Kane	216	0.13 (0.08–0.19)	221	0.22 (0.15–0.30)	222	0.13 (0.08–0.21)	220	0.15 (0.10–0.23)	–	–	0.22	NS
III: Z v. P, O, Q, R^d
Schooler–Kane	102	0.01 (0.001–0.06)	102	0.04 (0.01–0.12)	104	0.04 (0.01–0.12)	96	0.03 (0.010–0.10)	89	0.02 (0.005–0.09)	0.47	NS
Modified
Schooler–Kane	122	0.17 (0.10–0.28)	128	0.23 (0.15–0.36)	128	0.15 (0.08–0.28)	121	0.18 (0.11–0.30)	124	0.14 (0.08–0.26)	0.74	NS

NS, not significant; O, olanzapine; P, perphenazine; Q, quetiapine; R, risperidone; Z, ziprasidone

^a.

Patients with no tardive dyskinesia at baseline met none of the criteria for modified Schooler–Kane tardive dyskinesia or borderline tardive dyskinesia. Probability of having an event within 1 year is estimated with Poisson regression adjusted for the following covariates: baseline total Positive and Negative Syndrome Scale score, years taking antipsychotic medication (0–5, 6–20, 21+), and baseline Simpson–Angus Scale extrapyramidal side-effects (EPS) score (all items =0 normal, or EPS score >0). Italicised values highlight treatment conditions of primary interest in each data-set

^b.

Data-sets II and IV are not applicable in this analysis since patients stratified into Phase 1a at baseline are excluded

^c.

Excluding patients on ziprasidone

^d.

Including only ziprasidone cohort patients